logo-loader
RNS
viewDiurnal

Diurnal Group PLC - Director Dealings and Issue of Equity

RNS Number : 3368K
Diurnal Group PLC
21 April 2020
 

21 April 2020

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings and Issue of Equity

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following share dealings by Directors:

 

John Goddard, Non-Executive Director, was today issued and allotted 12,963 new Ordinary Shares at an effective price of nil pence per Ordinary Share as part of a pre-existing arrangement whereby he receives shares in the Company in lieu of part of his Non-executive director fees, issued from the Company's Employee Benefit Trust. Following the transaction, John Goddard has a total interest of 188,589 Ordinary Shares, representing 0.2% of the enlarged total voting rights in the Company.

 

Application will be made for admission of the 12,963 new Ordinary Shares, which is anticipated to occur at 8:00am on Monday 27 April 2020 ("Admission"). The New Ordinary Shares rank pari passu with the existing shares of the Company. Following issue of the New Ordinary Shares, the Company's issued ordinary share capital consists of 121,633,387 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights is 121,633,387.

 

The above figure of 121,633,387 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Details of the full notifications received by the Company are set out below:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

John Goddard

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-executive Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 5 pence each in Diurnal Group plc



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Acquisition of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Nil

12,963

 

 






d)

 

Aggregated information




- Aggregated volume

As above



- Price




e)

 

Date of the transaction

 

21 April 2020

f)

 

Place of the transaction

 

XLON

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: James Stearns




Cantor Fitzgerald Europe (Joint Broker)

+44 (0)20 7894 7000

Corporate Finance: Phil Davies, Will Goode, Michael Boot


Healthcare Equity Sales: Andrew Keith




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


 

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European-based specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFIFIASLILFII

Quick facts: Diurnal

Price: 30

Market: AIM
Market Cap: £36.49 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE